Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2013; 34(04): 283-291
DOI: 10.4103/0971-5851.125246
ORIGINAL ARTICLE

Cyclin D1 expression in multiple myeloma by immunohistochemistry: Case series of 14 patients and literature review

Somanath Padhi
Department of Pathology, Pondicherry Institute of Medical Sciences, Puducherry, India
,
Renu G’Boy Varghese
Department of Pathology, Pondicherry Institute of Medical Sciences, Puducherry, India
,
Anita Ramdas
Department of Pathology, Pondicherry Institute of Medical Sciences, Puducherry, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

Background: Cyclin D1 dysregulation is an early and unifying oncogenic event in patients of multiple myeloma (MM). This may be detected up to 30% cases by immunohistochemistry (IHC) and up to 40-50% cases by molecular studies. However, studies on the clinical significance of cyclin D1 dysregulation in MM have been inconclusive. We aimed to study the pattern of cyclin D1 expression in MM by IHC and correlate with selected clinicopathologic features. Materials and Methods: Formalin fixed, decalcified, bone marrow trephine sections from 14 symptomatic patients of MM (13 newly diagnosed and one relapsed) were subjected to cyclin D1 IHC by using a rabbit monoclonal antibody to cyclin D1 (clone EPR2241). Results: Cyclin D1 expression (in ≥10% tumor cell nuclei) was observed in 8 of 14 cases (57%). Cyclin D1 positive (+) group had significantly lower hemoglobin level (P = 0.03) than cyclin D1 negative (−) group (n = 6); though both groups showed no statistical significance (P > 0.05) in regard to age, gender, Durie and Salmon stage, lytic bone lesions, light chain phenotype, creatinine, calcium, lactate dehydrogenase, leukocyte and platelet count and bone marrow histology. Ten of 14 (71.5%) showed a favorable response (follow-up; 7 days to 34 months) to thalidomide and/or bortezomib based chemotherapeutic regimen. Four of eight cyclin D1+ patients showed complete response, two had a partial response (PR) and two died of the disease; whereas 4/6 cyclin D1− patients had PR, one refused definitive therapy and one was lost to follow-up (P > 0.05, Fischer′s exact test). Conclusion: IHC may be a feasible tool for the demonstration of cyclin D1 expression on adequately processed trephine biopsy specimen in MM patients in a resource poor setting. Negative IHC results should be correlated with molecular techniques for prognostication.

Keywords

Bone marrow - cyclin D1 - immunohistochemistry - multiple myeloma - prognosis


Publication History

Article published online:
19 July 2021

© 2013. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60.
  • 2 McKenna RW, Kyle RA, Kuehl WM, Grogan TM, Harris NL, Coupland RW. Plasma cell neoplasm. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. 4 th ed. Lyon: IARC; 2008. p. 200-12.
  • 3 International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the international myeloma working group. Br J Haematol 2003;121:749-57.
  • 4 Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020-8.
  • 5 Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood 2005;106:296-303.
  • 6 Marsaud V, Tchakarska G, Andrieux G, Liu JM, Dembele D, Jost B, et al. Cyclin K and cyclin D1b are oncogenic in myeloma cells. Mol Cancer 2010;9:103.
  • 7 Krieger S, Gauduchon J, Roussel M, Troussard X, Sola B. Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma. BMC Cancer 2006;6:238.
  • 8 Kelley TW, Baz R, Hussein M, Karafa M, Cook JR. Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen. Hum Pathol 2009;40:405-12.
  • 9 Chen MH, Qi C, Reece D, Chang H. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib. Hum Pathol 2012;43:858-64.
  • 10 Tasidou A, Roussou M, Terpos E, Kastritis E, Gkotzamanidou M, Gavriatopoulou M, et al. Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents. Am J Hematol 2012;87:734-6.
  • 11 Kojima M, Motoori T, Tamaki Y, Igarashi T, Matsumoto M, Shimizu K, et al. Cyclin D1 protein overexpression in extramedullary plasmacytoma: A clinicopathologic study of 11 cases. J Clin Exp Hematop 2009;49:53-6.
  • 12 Dawson MA, Opat SS, Taouk Y, Donovan M, Zammit M, Monaghan K, et al. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma. Clin Cancer Res 2009;15:714-22.
  • 13 Cook JR, Hsi ED, Worley S, Tubbs RR, Hussein M. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival. Am J Clin Pathol 2006;125:615-24.
  • 14 Bataille R, Durie BG, Grenier J, Sany J. Prognostic factors and staging in multiple myeloma: A reappraisal. J Clin Oncol 1986;4:80-7.
  • 15 Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol 1987;87:342-55.
  • 16 Smith A, Wisloff F, Samson D, UK Myeloma Forum, Nordic Myeloma Study Group, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132:410-51.
  • 17 Athanasiou E, Kaloutsi V, Kotoula V, Hytiroglou P, Kostopoulos I, Zervas C, et al. Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens. Am J Clin Pathol 2001;116:535-42.
  • 18 Yeung J, Chang H. Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma. J Clin Pathol 2008;61:832-6.
  • 19 Markovic O, Marisavljevic D, Cemerikic V, Suvajdzic N, Milic N, Colovic M. Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: Relationship to proliferative activity and prognostic significance. Med Oncol 2004;21:73-80.
  • 20 Pruneri G, Fabris S, Baldini L, Carboni N, Zagano S, Colombi MA, et al. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol 2000;156:1505-13.
  • 21 Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol 2000;113:831-7.
  • 22 Hoechtlen-Vollmar W, Menzel G, Bartl R, Lamerz R, Wick M, Seidel D. Amplification of cyclin D1 gene in multiple myeloma: Clinical and prognostic relevance. Br J Haematol 2000;109:30-8.
  • 23 Vasef MA, Medeiros LJ, Yospur LS, Sun NC, McCourty A, Brynes RK. Cyclin D1 protein in multiple myeloma and plasmacytoma: An immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod Pathol 1997;10:927-32.
  • 24 Lai R, Medeiros LJ, Wilson CS, Sun NC, Koo C, McCourty A, et al. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: Correlation with cyclin-D1 immunoreactivity. Mod Pathol 1998;11:642-7.
  • 25 Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
  • 26 Ngo BT, Felthaus J, Hein M, Follo M, Wider D, Ihorst G, et al. Monitoring bortezomib therapy in multiple myeloma: Screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome. Leuk Lymphoma 2010;51:1632-42.